


JOSH GREEN, M.D.
GOVERNOR
KE KIA'ĀINA



CATHY BETTS
DIRECTOR
KA LUNA HO'OKELE

JOSEPH CAMPOS II
DEPUTY DIRECTOR
KA HOPE LUNA HO'OKELE

TRISTA SPEER
DEPUTY DIRECTOR
KA HOPE LUNA HO'OKELE

STATE OF HAWAII
KA MOKU'ĀINA O HAWAI'I
DEPARTMENT OF HUMAN SERVICES
KA 'OIHANA MĀLAMA LAWELAWE KANAKA
Med-QUEST Division
Health Care Services Branch
Data Analysis and Provider Network Section
P. O. Box 700190
Kapolei, Hawaii 96709-0190

November 28, 2023

MEMORANDUM

MEMO NO.
QI-2340
CCS-2313
FFS 23-23

TO: QUEST Integration (QI) Health Plans
Community Care Services (CCS) Health Plan
Pharmacies, Physicians, Registered Nurse Practitioners

FROM: Judy Mohr Peterson, PhD 
Med-QUEST Division Administrator

SUBJECT: REIMBURSEMENT FOR THE ADMINISTRATION FEE OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS (LAIA) ADMINISTERED IN THE COMMUNITY SETTING.

The purpose of this memorandum is for the Med-QUEST Division (MQD) to provide guidance to QUEST Integration (QI) health plans, CCS, and the Medicaid FFS program regarding the administration fee for long-acting injectable antipsychotics (LAIA) when administered in the community setting.

LAIA represent a highly effective option for individuals facing challenging circumstances while needing to take medications regularly, such as individuals experiencing homelessness. However, these treatments often are an underutilized treatment for individuals with serious mental illness (SMI), especially among patients with first episode schizophrenia. LAIA can be dosed less frequently than oral antipsychotics (OAP) and provide better outcomes for patients with poor OAP medication adherence, preventing negative clinical outcomes such as symptom

relapse and hospitalizations^{i,ii}. In addition, meta-analysis of multiple studies found treatment with LAIA compared to OAP reduced all-cause mortality for patients with schizophreniaⁱⁱⁱ.

Some of the individuals who can benefit most from LAIA are best served when engaged by outreach in the community setting. This would include coordination with prescriber, outreach, travel, administration of the shot, tracking and follow up, taking supplies out to community, and coordination with case management. In order to decrease barriers and make these efforts sustainable, we are implementing a new administration fee.

Effective November 1, 2023, the rate for the administration of LAIA shall be increased to \$200.00 when performed in the community setting. Eligible LAIA include the long acting first- and second-generation antipsychotics; see table 1 below for examples. Eligible providers who can administer and bill for the administration fee include pharmacies, physicians, and registered nurse practitioners. Eligible places of service (POSs) other than clinic, hospital, or office settings that would qualify as a community setting include those listed below in Table 2.

Table 1

Listed below are examples of first and second generation LAIA that may be used for people with mental illness administered in community setting POS. Dosing intervals listed are recommendations, but the actual interval must be based on the ordering prescriber instructions. Payment of claims for LAIA is the responsibility of the QI or CCS Health plan in which the patient is enrolled. The below list is non-exclusive, and as new brand and generics LAIA are approved by the FDA these may be considered for use.

Name	Tradename	Dosage Form	Dosing Interval (Maintenance)*
<u>Aripiprazole monohydrate</u>	<i>Abilify Maintenna</i> <i>Abilify Asimtufii</i>	Vial, prefilled syringes	Monthly Every 2 months
<u>Aripiprazole lauroxil</u>	<i>Aristada Initio</i> <i>Aristada,</i>	Prefilled syringes	Initial Dose, monthly (441–882 mg), or q6 weeks (882 mg)
Fluphenazine decanoate	<i>Prolixin</i>	Vial	Every 2 weeks, up to every 6 weeks
Haloperidol decanoate	<i>Haldol</i>	Vial	Monthly

Name	Tradename	Dosage Form	Dosing Interval (Maintenance)*
<u>Paliperidone palmitate</u>	<i>Invega Sustenna, Xeplion</i>	Prefilled syringes	Monthly
<u>Paliperidone palmitate</u>	<i>Invega Trinza Invega Hafyera</i>	Prefilled syringes	Every 3 months Every 6 months
<u>Risperidone microspheres</u>	<i>Risperdal Consta Rykindo Perseris Uzedy</i>	Vial, Prefilled syringes	Every 2 weeks Monthly

*Dosing interval as recommended per manufacturer package instructions for maintenance dose.

Unlike the LAIA listed in table above, Olanzapine pamoate (Zyprexa Relprevv) is also a LAIA but not recommended for administration in community setting due to potential complications and prolonged observation time.

Table 2

The following are acceptable community setting POS codes that may be used to bill for the administration of LAIA listed above. These codes should be used on professional claims to specify the entity where service(s) were rendered:

Place of Service Code(s)^v	Place of Service Name	Place of Service Description
04	Homeless Shelter	A facility or location whose primary purpose is to provide temporary housing to homeless individuals (e.g., emergency shelters, individual or family shelters).
12	Home	Location, other than a hospital or other facility, where the patient receives care in a private residence.
13	Assisted Living Facility	Congregate residential facility with self-contained living units providing assessment of each resident's needs and on-site support 24 hours a day, 7 days a week, with the capacity to deliver or arrange for services including some health care and other services.
15	Mobile Unit	A facility/unit that moves from place-to-place equipped to provide preventive, screening, diagnostic, and/or treatment services.

16	Temporary Lodging	A short-term accommodation such as a hotel, campground, hostel, cruise ship or resort where the patient receives care, and which is not identified by any other POS code.
27	Outreach Site/ Street	A non-permanent location on the street or found environment, not described by any other POS code, where health professionals provide preventive, screening, diagnostic, and/or treatment services to unsheltered homeless individuals.
33	Custodial Care Facility	A facility which provides room, board, and other personal assistance services, generally on a long-term basis, and which does not include a medical component.

Billing Code, Rate and Covered Providers

Providers rendering services to an individual in an acceptable POS are responsible for determining and rendering appropriate and applicable eligible services. Reimbursement for rendered services is limited to the provider’s applicable scope of services and covered Medicaid services. The administration of LAIA at an accepted POS shall be reimbursed at \$200.00 when rendered and billed for payment by pharmacy, physician (MD or DO), or registered nurse practitioner (NP) or advanced practice registered nurse (APRN). Appropriate billed codes are the T1502 procedure code with the HK modifier. The list below provides additional detail.

Provider Type	PT Name	Code	Modifier	Amount
3	Pharmacy	T1502*	HK	\$200.00
8	MD-Medical Doctor/Physician	T1502*	HK	\$200.00
19	APRN	T1502*	HK	\$200.00
31	DO-Doctor of Osteopathy	T1502*	HK	\$200 00

*Procedure Code T1502 Description: ADMINISTRATION OF ORAL, INTRAMUSCULAR AND/OR SUBCUTANEOUS

Medical Assistants shall not administer the LAIA in the community setting POS at this time.

Questions and Inquiries

For questions or inquiries regarding this memo, please contact Provider Hotline Monday through Friday during standard business hours, 7:45am-4:30pm HST at (808) 692-8099 or (833) 909-3630 for neighbor islands and via email HCSBInquiries@dhs.hawaii.gov.

-
- i [Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis](#). Lin D, Thompson-Leduc P, Ghelerter I, Nguyen H, Lafeuille MH, Benson C, et al. *CNS Drugs*. 2021;35(5):469–81. Epub 2021/04/29. doi: 10.1007/s40263-021-00815-y
- ii [Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: A systematic review and meta-analysis](#). Lian L, Kim DD, Procyshyn RM, Fredrikson DH, Cázares D, Honer WG, Barr AM. *Early Interv Psychiatry*. 2022 Jun;16(6):589-599. doi: 10.1111/eip.13202. Epub 2021 Jul 14. PMID: 34263540
- iii [Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors](#). Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, Smith N, Bitter I, Gorwood P, Taipale H, Tiihonen J. *World Psychiatry*. 2022 Jun;21(2):248-271. doi: 10.1002/wps.20994. PMID: 35524619
- iv Place of Service Code Set | CMS. <https://www.cms.gov/medicare/coding-billing/place-of-service-codes>